Search
for
Sort by
Research 30 of 427
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Hand-Foot and Stump Syndrome to Sorafenib
- Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- Disorders of the skin appendages
- Skin problems in the long‐distance runner 2500 years after the Battle of Marathon
- A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib
- Transient perforating folliculitis induced by sorafenib
- Cutaneous changes in patients with chronic renal failure on hemodialysis
- Nails and hair
- Involvement of scalp and nails in lupus erythematosus
- Nails and hair
- Telogen effluvium and associated incidence of abnormal serum ferritin, zinc, 25-hydroxy vitamin D, and thyroid-stimulating hormone
- Safety and efficacy of tavaborole (AN2690), a novel boron-based molecule, in 3 phase II trials for the topical treatment of toenail onychomycosis
- PROFILE OF SKIN CHANGES AND ITS ASSOCIATION WITH BIOCHEMICAL PARAMETERS IN HAEMODIALYSIS PATIENTS
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Hair and nail involvement in lupus erythematosus
- Cutaneous drug reactions
- Sorafenib-induced Facial Acneiform Eruption
- The histopathologic spectrum of psoriasis
- Alternative uses of dermoscopy in daily clinical practice: An update
- Presence and future of dermoscopy
- Diseases of the Hair and Nails
- Dermatologic Adverse Events from Cancer Treatments
- The Skin and Subcutaneous Tissues
- Pediatric Lichen: Epidemiological and Clinical Characteristics in Children
- General Dermatology
- Long-term treatment within a maximum of 96 weeks of tinea unguium with long-pulsed neodymium-doped yttrium aluminum garnet laser
- Minimal systemic exposure of a new topical triazole antifungal, efinaconazole 10% solution, in patients with severe onychomycosis following 28-day treatment
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer